|
|
Azmacort (Triamcinolone acetonide)
|
 |
Respiratory agent
|
 |
Respiratory inhalant product
|
 |
Azmacort inhalation aerosol is indicated in the maintenance/prophylactic treatment of asthma. Azmacort inhalation aerosol is also indicated for asthma patients who require systemic corticosteroid administration, and when adding Azmacort may reduce or eliminate the need for the systemic corticosteroids.
|
 |
Adults: 2 inhalations 3 or 4 times daily; maximum dose 16 inhalations/day. Pediatric patients 6 to 12 years: 1 or 2 inhalations 3 or 4 times daily; maximum dosage 12 inhalations/day. Use lowest effective dose before or after meal.
|
 |
Category D
|
 |
Hoarseness, dry throat and mouth, increase wheezing, cough, and facial swelling.
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
| | |
If you want your friend to read or know about this article, Click here
 |
|
|
